KYG9TY5A1016 - Common Stock
ZURA stock results show that Zura Bio beat analyst estimates for earnings per share the second quarter of 2024.
Biotech company Redx Pharma Plc is set to pull its shares from the London Stock Exchange’s smallest market, citing liquidity constraints and saying it will attract investors more easily as a private company.
ZURA stock results show that Zura Bio missed analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Zura Bio (NASDAQ:ZURA) just reported results for the fourth quarter of 2023.Zur...
Zura Bio (NASDAQ:ZURA) has appointed Robert Lisicki as President and Chief Operating Officer.Mr.
Oppenheimer has initiated coverage of Zura Bio (ZURA) with an outperform rating, citing the revenue potential of its drug ZB-106, also known as tibulizumab. Read more here.
Zura Bio (ZURA) to be added to the Russell 2000 and Russell 3000 Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on...
The biotech stock continued its rise in June.
Tingo Group (TIO) stock is taking a beating on Tuesday after the company was hit with a short report from Hindenburg Research.
McCormick (MKC) stock is extra spicy on Tuesday after the company got a double upgrade from Bank of America analyst Peter Galbo.